184 related articles for article (PubMed ID: 19018880)
1. Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression.
Smith CJ; Phillips AN; Dauer B; Johnson MA; Lampe FC; Youle MS; Tyrer M; Staszewski S
HIV Med; 2009 Jan; 10(1):19-27. PubMed ID: 19018880
[TBL] [Abstract][Full Text] [Related]
2. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
Phillips AN; Staszewski S; Lampe F; Youle MS; Klauke S; Bickel M; Sabin CA; Doerr HW; Johnson MA; Loveday C; Miller V; ;
J Infect Dis; 2002 Oct; 186(8):1086-91. PubMed ID: 12355358
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
Abgrall S; Duval X; Joly V; Descamps D; Matheron S; Costagliola D;
Clin Infect Dis; 2003 Dec; 37(11):1517-26. PubMed ID: 14614675
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
[TBL] [Abstract][Full Text] [Related]
7. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.
Trotta MP; Cozzi-Lepri A; Ammassari A; Vecchiet J; Cassola G; Caramello P; Vullo V; Soscia F; Chiodera A; Ladisa N; Abeli C; Cauda R; Buonuomi AR; Antinori A; d'Arminio Monforte A;
Clin Infect Dis; 2010 Aug; 51(4):456-64. PubMed ID: 20597690
[TBL] [Abstract][Full Text] [Related]
8. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression.
Cambiano V; Lampe FC; Rodger AJ; Smith CJ; Geretti AM; Lodwick RK; Holloway J; Johnson M; Phillips AN
HIV Med; 2010 Mar; 11(3):216-24. PubMed ID: 20002781
[TBL] [Abstract][Full Text] [Related]
9. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
Mocroft A; Ledergerber B; Viard JP; Staszewski S; Murphy M; Chiesi A; Horban A; Hansen AB; Phillips AN; Lundgren JD;
J Infect Dis; 2004 Dec; 190(11):1947-56. PubMed ID: 15529259
[TBL] [Abstract][Full Text] [Related]
10. Stability of antiretroviral regimens in patients with viral suppression.
Lodwick RK; Smith CJ; Youle M; Lampe FC; Tyrer M; Bhagani S; Chaloner C; Sabin CA; Johnson MA; Phillips AN
AIDS; 2008 May; 22(9):1039-46. PubMed ID: 18520347
[TBL] [Abstract][Full Text] [Related]
11. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
Reekie J; Mocroft A; Sambatakou H; Machala L; Chiesi A; van Lunzen J; Clumeck N; Kirk O; Gazzard B; Lundgren JD;
AIDS; 2008 Nov; 22(17):2381-90. PubMed ID: 18981778
[TBL] [Abstract][Full Text] [Related]
12. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
Mussini C; Manzardo C; Johnson M; Monforte Ad; Uberti-Foppa C; Antinori A; Gill MJ; Sighinolfi L; Borghi V; Lazzarin A; Miró JM; Sabin C;
AIDS; 2008 Nov; 22(18):2461-9. PubMed ID: 19005269
[TBL] [Abstract][Full Text] [Related]
13. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
[TBL] [Abstract][Full Text] [Related]
14. Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999.
Mocroft A; Horban A; Clotet B; d'Arminio Monforte A; Bogner JR; Aldins P; Staub T; Antunes F; Katlama C; Lundgren JD;
HIV Med; 2008 Jan; 9(1):41-6. PubMed ID: 18199171
[TBL] [Abstract][Full Text] [Related]
15. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy.
Sungkanuparph S; Groger RK; Overton ET; Fraser VJ; Powderly WG
HIV Med; 2006 Oct; 7(7):437-41. PubMed ID: 16925729
[TBL] [Abstract][Full Text] [Related]
16. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
17. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
[TBL] [Abstract][Full Text] [Related]
18. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
20. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients.
Glass TR; De Geest S; Hirschel B; Battegay M; Furrer H; Covassini M; Vernazza PL; Bernasconi E; Rickenboch M; Weber R; Bucher HC;
Antivir Ther; 2008; 13(1):77-85. PubMed ID: 18389901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
